Holen Sie sich die Stockscreener-App
1.445
4.93%
-0.075
Vorhandelsmarkt:
1.46
0.015
+1.04%
Schlusskurs vom Vortag:
$1.52
Offen:
$1.48
24-Stunden-Volumen:
1.39M
Relative Volume:
0.52
Marktkapitalisierung:
$324.74M
Einnahmen:
$95,000
Nettoeinkommen (Verlust:
$-327.27M
KGV:
-0.6816
EPS:
-2.12
Netto-Cashflow:
$-239.25M
1W Leistung:
+1.76%
1M Leistung:
+30.18%
6M Leistung:
+12.02%
1J Leistung:
-35.92%
1-Tages-Spanne:
$1.41
$1.51
1-Wochen-Bereich:
$1.30
$1.52
52-Wochen-Spanne:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALLO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.445 | 341.59M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Will Allogene Therapeutics Inc. stock benefit from green energy trendsForecast Cut & Stock Market Timing Techniques - Newser
Allogene Therapeutics showcases ALPHA3 study at ASH25 - Traders Union
Allogene Therapeutics CEO unveils pipeline at Piper Sandler - Traders Union
Allogene Therapeutics Up 19%, But Some Insiders Miss Out - 富途牛牛
U.S. CAR T-Cell Therapies Market Grows at 30.4% CAGR, Soars USD 42.61 Billion by 2035 - GlobeNewswire Inc.
Could a New Alternative to a Bespoke Treatment Change the Future of Cancer Care? - Katie Couric Media
Allogene upgraded at Citizens after Q4 update - MSN
Allogene Therapeutics redefines CAR T-cell therapy with allogeneic products - Traders Union
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Can SBC Exports Limited Deliver Through Market Peaks and TroughsResistance Zone Identification & Build Winning Portfolio - earlytimes.in
Allogene Therapeutics reports Q3 EPS (19c), consensus (23c) - MSN
Allogene Therapeutics unveils ALLO-329 to combat autoimmune diseases - Traders Union
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, - openPR.com
Analyzing Allogene Therapeutics Inc. with multi timeframe chartsWeekly Stock Report & Fast Moving Trade Plans - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Why Allogene Therapeutics Inc. stock remains on watchlistsPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Allogene Therapeutics advances ALLO-329 cell therapy to transform autoimmune care - Traders Union
ALLO (Allogene Therapeutics) Construction In Progress : $0.00 Mil (As of Sep. 2025) - GuruFocus
Will breakout in Allogene Therapeutics Inc. lead to full recovery2025 Volume Leaders & Free Verified High Yield Trade Plans - newser.com
What candlestick patterns are forming on Allogene Therapeutics Inc.Weekly Trend Recap & Reliable Price Breakout Signals - newser.com
Allogene Therapeutics at Jefferies Conference: Strategic Advances in CAR-T Therapy - Investing.com Canada
VP Beneski Files To Sell 786 Of Allogene Therapeutics Inc [ALLO] - TradingView
Applying Elliott Wave Theory to Allogene Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Allocation Plans - newser.com
Risk adjusted return profile for Allogene Therapeutics Inc. analyzedQuarterly Trade Report & Low Risk Entry Point Guides - newser.com
Allogene Therapeutics CEO advocates cell therapy innovation at Jefferies conference - Traders Union
Published on: 2025-11-14 03:15:46 - newser.com
How sentiment analysis helps forecast Allogene Therapeutics Inc.2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
Using AI based signals to follow Allogene Therapeutics Inc.2025 Market Outlook & Momentum Based Trading Ideas - newser.com
Published on: 2025-11-12 16:30:24 - newser.com
November 2025's Promising Penny Stocks To Watch - simplywall.st
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):